ABOUT COMPANY :
Hetero is a globally renowned vertically integrated pharmaceutical player engaged in research and development, manufacturing, and marketing of high-quality chemical and biologic medicines across diverse therapeutic areas. Backed by 27+ years of expertise in the pharmaceutical industry, Hetero’s strategic business areas spread across APIs, Global Generics, Biosimilars and Custom Pharmaceutical Services. The company is among the largest producers of Active Pharmaceutical Ingredients (APIs) in the world.
Hetero has 36 state-of-the-art manufacturing facilities
strategically located worldwide, which has been approved by top pharma
regulatory bodies of the world. Our portfolio includes 300+ products
encompassing major therapeutic categories such as HIV/AIDS, Oncology,
Cardiovascular, Neurology, Hepatitis, Nephrology etc. Hetero has a strong
global presence in over 126 countries and focusses on making affordable
medicines accessible to patients worldwide.
Over
the years, Hetero has established its strong leadership in ARVs and Antiviral
therapies and caters to 40% of existing global demand for Anti-Retroviral (ARV)
APIs and Finished Dosage Forms (FDFs) used in HIV/AIDS treatment.
A track record of responding to Global Public Health
Emergencies
The
highlight of Hetero’s 27+ years of existence has been its responsive actions to
mitigate pandemics and life-threatening diseases afflicting communities across
the world. By partnering with innovators for developing Oseltamivir to fight
against Swine Flu Pandemic to enabling access to affordable Hepatitis C
medicines in underdeveloped countries, Hetero has always endeavoured to do its
bit at times of global health crises and save precious lives.
Since
the onset of the Covid-19 pandemic, Hetero has been proactive in responding to
the various challenges surrounding it. It has been the first company to launch
the licensed version of generic Remdesivir under the brand name ‘Covifor’ in
India for treating severely infected patients and followed it up with
Favipiravir (Favivir) to provide succor to those affected by mild and moderate
symptoms. As of today, the company is among the largest manufacturers of
Remdesivir globally.
Illustrating
its continuing commitment to play its part in the global fight against the
pandemic, Hetero has entered into an agreement with the Russian Direct Investment
Fund (RDIF) as a manufacturing partner for producing 100 million doses of the
Sputnik V vaccine per year. This development also showcases Hetero’s enduring
spirit of collaboration and penchant for contributing to global health and
well-being.
For more updates
follow
Thank you for visiting my website, Visit again
for
latest pharma updates
No comments:
Post a Comment